Korean J Gastroenterol.  2011 Apr;57(4):207-212. 10.4166/kjg.2011.57.4.207.

Second Line Chemotherapy for Pancreatic Cancer

Affiliations
  • 1Division of Gastroenterology, Department of Internal Medicine, Yonsei Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea. sensass@yuhs.ac

Abstract

Pancreatic cancer is a very lethal cancer. It is the 5th most common cause for cancer related mortality in Korea. Most of patients have unresectable pancreatic cancer, and systemic chemotherapy remains the only treatment option for them. Gemcitabine has been adopted as the standard first-line agent for advanced pancreatic cancer, but the progression free survival with gemcitabine is short. Many of patients need further treatment. We reviewed the clinical trials of second line chemotherapy for gemcitabine refractory pancreatic cancer and tried to show currently available treatment options.

Keyword

Pancreatic Cancer; Chemotherapy

MeSH Terms

Antibodies, Monoclonal/therapeutic use
Antineoplastic Agents/therapeutic use
Camptothecin/therapeutic use
Deoxycytidine/analogs & derivatives/therapeutic use
Drug Therapy, Combination
Fluorouracil/therapeutic use
Humans
Organoplatinum Compounds/therapeutic use
Pancreatic Neoplasms/*drug therapy
Taxoids/therapeutic use
Full Text Links
  • KJG
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error